Is adjuvant therapy necessary for peritoneal cytology-positive surgical-pathologic Stage I endometrial cancer? Preliminary results
Dede, M.; Yenen, M.C.; Goktolga, U.; Duru, N.K.; Guden, M.; Dilek, S.; Pabuccu, R.
European Journal of Gynaecological Oncology 25(5): 591-593
2004
ISSN/ISBN: 0392-2936 PMID: 15493172 Document Number: 583346
Objective: To compare the clinical and laboratory findings between adjuvant therapy performed and not performed on peritoneal cytology-positive patients with cytology-negative cases of surgical-pathologic Stage I endometrial cancer. Methods: Twelve peritoneal cytology-positive and 12 negative surgical-pathologic Stage I endometrial cancer cases were used in the study. Adjuvant radiotherapy was performed for six cytology-positive patients (group I); no adjuvant therapy was performed for six cytology-positive (group II) and 12 cytology-negative patients (control group). Pelvic examination, vaginal cytology, serum CA125 levels and routine blood tests were checked at two-month intervals for two years and at six-month intervals for the third year. Abdominopelvic computerized tomography was planned annually. Results: There was no statistically significant difference among the three groups and no recurrence in any group. Conclusion: We do not recommend adjuvant therapy for cytology-positive patients if the tumor is confined to the uterus.